CA3178181A1 - Composition contraceptive presentant des effets cardiovasculaires reduits - Google Patents
Composition contraceptive presentant des effets cardiovasculaires reduitsInfo
- Publication number
- CA3178181A1 CA3178181A1 CA3178181A CA3178181A CA3178181A1 CA 3178181 A1 CA3178181 A1 CA 3178181A1 CA 3178181 A CA3178181 A CA 3178181A CA 3178181 A CA3178181 A CA 3178181A CA 3178181 A1 CA3178181 A1 CA 3178181A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- risk
- estetrol
- change
- cycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155571.5 | 2018-02-07 | ||
| EP18155571 | 2018-02-07 | ||
| EP18160586.6 | 2018-03-07 | ||
| EP18160586 | 2018-03-07 | ||
| CA3089804A CA3089804A1 (fr) | 2018-02-07 | 2019-02-07 | Composition contraceptive presentant des effets cardiovasculaires reduits |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3089804A Division CA3089804A1 (fr) | 2018-02-07 | 2019-02-07 | Composition contraceptive presentant des effets cardiovasculaires reduits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3178181A1 true CA3178181A1 (fr) | 2019-08-15 |
Family
ID=65278388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3089804A Pending CA3089804A1 (fr) | 2018-02-07 | 2019-02-07 | Composition contraceptive presentant des effets cardiovasculaires reduits |
| CA3178181A Pending CA3178181A1 (fr) | 2018-02-07 | 2019-02-07 | Composition contraceptive presentant des effets cardiovasculaires reduits |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3089804A Pending CA3089804A1 (fr) | 2018-02-07 | 2019-02-07 | Composition contraceptive presentant des effets cardiovasculaires reduits |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP3749327A1 (fr) |
| JP (2) | JP2021513507A (fr) |
| KR (1) | KR102717921B1 (fr) |
| CN (2) | CN115429806A (fr) |
| AU (1) | AU2019219070B2 (fr) |
| CA (2) | CA3089804A1 (fr) |
| CL (1) | CL2020002017A1 (fr) |
| EC (1) | ECSP20054822A (fr) |
| GE (2) | GEAP202215414A (fr) |
| IL (1) | IL276584B2 (fr) |
| JO (1) | JOP20200169A1 (fr) |
| MA (1) | MA51733A (fr) |
| NZ (1) | NZ766027A (fr) |
| PH (1) | PH12020500601A1 (fr) |
| PY (1) | PY1908892A (fr) |
| SG (1) | SG11202007163WA (fr) |
| TW (1) | TWI845496B (fr) |
| UA (1) | UA126746C2 (fr) |
| UY (1) | UY38075A (fr) |
| WO (1) | WO2019154899A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3701944B1 (fr) | 2015-06-18 | 2021-12-08 | Estetra SRL | Unité posologique orodispersible contenant un composant d'estétrol |
| MA44206B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
| CU24523B1 (es) | 2015-06-18 | 2021-06-08 | Estetra Sprl | Unidad de dosificación orodispersable que contiene un componente estetrol |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CA3178291A1 (fr) | 2016-08-05 | 2018-04-12 | Estetra Srl | Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles |
| EP3781171B1 (fr) | 2018-04-19 | 2022-02-09 | Estetra SRL | Composés et leurs utilisations pour soulager des symptômes associés à la ménopause |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022248733A1 (fr) | 2021-05-28 | 2022-12-01 | Neuralis Sa | Utilisation d'estétrol dans le traitement de maladies infectieuses respiratoires |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| DK1390042T3 (da) * | 2001-05-23 | 2008-03-31 | Pantarhei Bioscience Bv | System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse |
| EP1535618A1 (fr) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Préparation pharmaceutique pour le traitement hormonal continuel sur plus de 21-28 jours comprenant deux compositions d'estrogène et/ou de progestine |
| EP2432474A1 (fr) * | 2009-05-22 | 2012-03-28 | Bayer Pharma Aktiengesellschaft | Médicament à administrer oralement, contenant au moins un strogène et/ou au moins un gestagène et au moins une souche bactérienne probiotique |
| WO2012055840A1 (fr) * | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels |
| DK3079671T3 (en) * | 2013-12-12 | 2017-12-11 | Donesta Bioscience B V | Orally disintegrating solid dosage unit containing an estetrol component |
| CA3178291A1 (fr) * | 2016-08-05 | 2018-04-12 | Estetra Srl | Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles |
| KR102780201B1 (ko) | 2016-10-28 | 2025-03-12 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
-
2019
- 2019-02-07 IL IL276584A patent/IL276584B2/en unknown
- 2019-02-07 GE GEAP202215414A patent/GEAP202215414A/en unknown
- 2019-02-07 CA CA3089804A patent/CA3089804A1/fr active Pending
- 2019-02-07 EP EP19703103.2A patent/EP3749327A1/fr active Pending
- 2019-02-07 NZ NZ766027A patent/NZ766027A/en unknown
- 2019-02-07 AU AU2019219070A patent/AU2019219070B2/en active Active
- 2019-02-07 WO PCT/EP2019/052980 patent/WO2019154899A1/fr not_active Ceased
- 2019-02-07 EP EP22199066.6A patent/EP4140489A1/fr active Pending
- 2019-02-07 JP JP2020538823A patent/JP2021513507A/ja active Pending
- 2019-02-07 JO JOP/2020/0169A patent/JOP20200169A1/ar unknown
- 2019-02-07 UY UY38075A patent/UY38075A/es not_active Application Discontinuation
- 2019-02-07 PY PY201901908892A patent/PY1908892A/es unknown
- 2019-02-07 KR KR1020207025456A patent/KR102717921B1/ko active Active
- 2019-02-07 GE GEAP201915414A patent/GEP20227407B/en unknown
- 2019-02-07 MA MA051733A patent/MA51733A/fr unknown
- 2019-02-07 UA UAA202005421A patent/UA126746C2/uk unknown
- 2019-02-07 CA CA3178181A patent/CA3178181A1/fr active Pending
- 2019-02-07 CN CN202211257175.1A patent/CN115429806A/zh active Pending
- 2019-02-07 SG SG11202007163WA patent/SG11202007163WA/en unknown
- 2019-02-07 CN CN201980012248.0A patent/CN111683664A/zh active Pending
- 2019-02-11 TW TW108104465A patent/TWI845496B/zh active
-
2020
- 2020-07-13 PH PH12020500601A patent/PH12020500601A1/en unknown
- 2020-07-31 CL CL2020002017A patent/CL2020002017A1/es unknown
- 2020-09-04 EC ECSENADI202054822A patent/ECSP20054822A/es unknown
-
2023
- 2023-09-28 JP JP2023168039A patent/JP7651645B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102717921B1 (ko) | 2024-10-16 |
| MA51733A (fr) | 2020-12-16 |
| IL276584A (en) | 2020-09-30 |
| PY1908892A (es) | 2019-10-15 |
| GEAP202215414A (en) | 2022-04-25 |
| AU2019219070B2 (en) | 2024-12-19 |
| IL276584B2 (en) | 2024-10-01 |
| CN111683664A (zh) | 2020-09-18 |
| CL2020002017A1 (es) | 2020-12-04 |
| WO2019154899A1 (fr) | 2019-08-15 |
| PH12020500601A1 (en) | 2021-05-17 |
| UY38075A (es) | 2019-10-01 |
| SG11202007163WA (en) | 2020-08-28 |
| JOP20200169A1 (ar) | 2020-07-07 |
| KR20200118464A (ko) | 2020-10-15 |
| JP2024009834A (ja) | 2024-01-23 |
| JP2021513507A (ja) | 2021-05-27 |
| JP7651645B2 (ja) | 2025-03-26 |
| NZ766027A (en) | 2026-03-27 |
| ECSP20054822A (es) | 2020-12-31 |
| EP4140489A1 (fr) | 2023-03-01 |
| IL276584B1 (en) | 2024-06-01 |
| CN115429806A (zh) | 2022-12-06 |
| EP3749327A1 (fr) | 2020-12-16 |
| UA126746C2 (uk) | 2023-01-18 |
| AU2019219070A1 (en) | 2020-09-24 |
| GEP20227407B (en) | 2022-08-25 |
| CA3089804A1 (fr) | 2019-08-15 |
| TWI845496B (zh) | 2024-06-21 |
| TW202011967A (zh) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019219070B2 (en) | Contraceptive composition with reduced cardiovascular effects | |
| US20250360147A1 (en) | Methods using combined oral contraceptive compositions with reduced cardiovascular effects | |
| Klipping et al. | Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism | |
| JP6557298B2 (ja) | 副作用（ｖｔｅリスク、頭痛）を軽減し、月経困難症および月経痛の症状を軽減する方法 | |
| De Leo et al. | Hormonal contraceptives: pharmacology tailored to women's health | |
| Stanczyk et al. | Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations | |
| KR102780201B1 (ko) | 월경통 및 생리통의 관리방법 | |
| Podfigurna et al. | Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone) | |
| TWI472332B (zh) | 口服避孕療法 | |
| US20030191096A1 (en) | Method of hormonal therapy | |
| HK40081220A (en) | Contraceptive composition with reduced cardiovascular effects | |
| EA048171B1 (ru) | Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы | |
| EA048537B1 (ru) | Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы | |
| Aldrighi et al. | Lipid profile in women over 35 years old using triphasic combined oral contraceptives | |
| Antoniou-Tsigkos et al. | Combined oral contraceptives: Why, when, where? | |
| Gaspard et al. | ORIGINAL STUDY | |
| JP2008527018A (ja) | 避妊用医薬製剤 | |
| Shoupe et al. | History Pharmacology Metabolic Effects, Side Effects and Health Benefits | |
| Contraceptive et al. | PrOVRAL® 21 | |
| Britschgi et al. | Combined oral hormonal contraception–an update | |
| Standard et al. | H3B 2K4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220930 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240729 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260323 |